Canaccord Genuity Group Cuts Prestige Consumer Healthcare (NYSE:PBH) Price Target to $88.00

Prestige Consumer Healthcare (NYSE:PBH) had its price objective cut by Canaccord Genuity Group from $100.00 to $88.00 in a research note released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also recently commented on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Wednesday, October 8th. Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Thursday, September 4th. Wall Street Zen lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Sidoti raised shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price objective for the company in a research note on Wednesday, September 24th. Finally, Jefferies Financial Group cut their price objective on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a research report on Monday, October 27th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $85.33.

Prestige Consumer Healthcare Stock Performance

NYSE PBH opened at $59.85 on Friday. The business has a 50 day moving average price of $62.98 and a 200 day moving average price of $73.14. The company has a market capitalization of $2.95 billion, a P/E ratio of 14.05, a PEG ratio of 1.93 and a beta of 0.41. Prestige Consumer Healthcare has a 1-year low of $59.51 and a 1-year high of $90.04. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The company had revenue of $274.11 million for the quarter, compared to the consensus estimate of $257.14 million. During the same period in the previous year, the business earned $1.09 earnings per share. Prestige Consumer Healthcare’s quarterly revenue was down 3.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Sell-side analysts expect that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Institutional Trading of Prestige Consumer Healthcare

A number of hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC grew its stake in Prestige Consumer Healthcare by 4.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock worth $100,893,000 after acquiring an additional 70,376 shares during the period. Kayne Anderson Rudnick Investment Management LLC grew its position in shares of Prestige Consumer Healthcare by 45.3% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company’s stock valued at $135,903,000 after purchasing an additional 493,199 shares during the period. Geode Capital Management LLC increased its stake in Prestige Consumer Healthcare by 0.7% in the second quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company’s stock valued at $112,843,000 after purchasing an additional 9,455 shares during the last quarter. Invesco Ltd. lifted its position in Prestige Consumer Healthcare by 24.7% during the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company’s stock worth $113,635,000 after buying an additional 261,537 shares during the period. Finally, Congress Asset Management Co. lifted its position in Prestige Consumer Healthcare by 1.8% during the second quarter. Congress Asset Management Co. now owns 1,009,595 shares of the company’s stock worth $80,616,000 after buying an additional 18,015 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.